Expert Commentary

46 experts pen open letter to the FDA on uterine power morcellation

OBG Manag. 2015 December;27(12)
By
Eva Chalas, MD
Author and Disclosure Information

An interview with Eva Chalas, MD

 

References

As gynecologists are well aware, in November 2014, the FDA issued a safety communication, warning “against the use of laparoscopic power morcellators in the majority of women undergoing myomectomy or hysterectomy for treatment of fibroids.” Now, a group of 46 experts in gynecologic surgery, including Dr. Eva Chalas, question the FDA’s decision and provide their own clinical recommendations for FDA consideration.

In this interview with Dr. Chalas, she discusses:

  • why this letter needed to be written now
  • why, as an oncologist, she felt she needed to sign the letter
  • concerns with the data the FDA used to make their recommendation 1 year ago
  • the effects of the FDA’s warning over time
  • more.

Click here to read the open letter to the FDA.

Recommended Reading

RFVTA system offers alternative to myomectomy
MDedge ObGyn
Radiofrequency volumetric thermal ablation for symptomatic uterine fibroids
MDedge ObGyn
Patient denies consent to endometriosis treatment
MDedge ObGyn
2015 Update on osteoporosis
MDedge ObGyn
Managing complications at the time of vaginal hysterectomy
MDedge ObGyn
“Where is it safe to practice obstetrics?” is a broader question
MDedge ObGyn
Annual screening mammography beginning at age 40 saves the most lives
MDedge ObGyn
Does the discontinuation of menopausal hormone therapy affect a woman’s cardiovascular risk?
MDedge ObGyn
Treatment options for adenomyosis supported by limited high-quality data
MDedge ObGyn
AES: Hormonal contraceptives can boost seizures in epileptics
MDedge ObGyn

Related Articles